Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Codiak BioSciences, Inc.CDAK · Entity 114958 | Director | June 17, 2022 | June 21, 2022 |
| Shattuck Labs, Inc.STTK · Entity 5224 | Chief Medical Officer | June 30, 2026 | July 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Codiak BioSciences, Inc.
Report date June 17, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2032-06-16 | Direct | 7,500 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 7,500 · Balance 7,500 F1: This option shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,500 |
Reported balance
After 2022-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-17 · Grant · Acquired 1,500 · Balance 1,500 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: On June 17, 2022, the reporting person was granted 1,500 restricted stock units, which shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: On June 17, 2022, the reporting person was granted 1,500 restricted stock units, which shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders.
Shattuck Labs, Inc.
Report date June 30, 2026 · Filed July 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,219 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Sale · Disposed 30,000 · Balance 136,219 F1: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.62 to $7.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.62 to $7.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 3, 2026 00:15 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 30,000 | $7.01 | $210,300.00 |
DisclosureSEC source: 0001193125-26-295148 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,219 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.62 to $7.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 30,000 | $6.61 | $198,300.00 |
DisclosureSEC source: 0001193125-26-224669 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,219 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.41 to $7.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 21:14 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 3,195 | $4.15 | $13,259.25 |
DisclosureSEC source: 0001193125-26-024489 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,219 Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:45 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock · Derivative | 487,800 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-011837 · ownership.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,800 Underlying: Common Stock · 487,800 shares Expires 2036-01-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 487,800 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:45 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 6,851 | $4.75 | $32,542.25 |
DisclosureSEC source: 0001193125-26-011837 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,414 Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 23:04 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock · Derivative | 206,200 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000950170-25-010004 · ownership.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,200 Underlying: Common Stock · 206,200 shares Expires 2035-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 206,200 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 23:04 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 3,211 | $1.16 | $3,724.76 |
DisclosureSEC source: 0000950170-25-010004 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,265 Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:43 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 6,884 | $1.19 | $8,191.96 |
DisclosureSEC source: 0000950170-25-004939 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,476 Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,920 | $9.99 | $29,170.80 |
DisclosureSEC source: 0000950170-24-009382 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,360 Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:31 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 92,950 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-24-004648 · ownership.xml · derivative · entry 3 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,950 Underlying: Common Stock · 92,950 shares Expires 2034-01-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 92,950 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:31 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,987 | $10.09 | $30,138.83 |
DisclosureSEC source: 0000950170-24-004648 · ownership.xml · nonDerivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,280 Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:31 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 46,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-004648 · ownership.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,267 F1 · shares: Consists of 46,475 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 69,750 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000899243-23-002884 · doc4.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,750 Underlying: Common Stock · 69,750 shares Expires 2033-01-25 F2 · derivative.exercise_date: This option represents a right to purchase a total of 69,750 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 37,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002884 · doc4.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,792 F1 · shares: Consists of 37,875 restricted stock units, which will vest in four equal annual installments beginning on January 25, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:12 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,987 | $3.03 | $9,050.61 |
DisclosureSEC source: 0000899243-23-001683 · doc4.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,917 Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:43 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023392 · doc4.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On June 17, 2022, the reporting person was granted 1,500 restricted stock units, which shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders. F3 · derivative.expiration_date: On June 17, 2022, the reporting person was granted 1,500 restricted stock units, which shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:43 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-22-023392 · doc4.xml · derivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: This option shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:45 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 69,475 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0000899243-22-001797 · doc4.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,475 Underlying: Common Stock · 69,475 shares Expires 2032-01-10 F2 · derivative.exercise_date: This option represented a right to purchase a total of 69,475 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2023, with the remaining three quarters vesting in equal monthly installments through January 10, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:45 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 34,738 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001797 · doc4.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,904 F1 · shares: Consists of 34,738 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:15 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0000899243-21-033449 · doc4.xml · derivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-15 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments over 3 years. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:59 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,259 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000899243-21-032549 · doc4.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,259 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represented a right to purchase a total of 5,863 shares of the Issuer's common stock and has vested in full. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:59 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 4,259 | $0.01 | $42.59 |
DisclosureSEC source: 0000899243-21-032549 · doc4.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2021 Filed Jan 20, 2021 00:50 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,604 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000899243-21-002399 · doc4.xml · derivative · entry 2 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,259 Underlying: Common Stock · 1,604 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 5,863 shares of the Issuer's common stock and will vest in equal monthly installments through July 24, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 05, 2021 Filed Jan 20, 2021 00:50 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 1,604 | $0.01 | $16.04 |
DisclosureSEC source: 0000899243-21-002399 · doc4.xml · nonDerivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:50 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 27,563 | $0.00 Strike: $53.02 | $0.00 |
DisclosureSEC source: 0000899243-20-035210 · doc4.xml · derivative · entry 1 Pandite Arundathy N. · CIK 0001827232 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,563 Underlying: Common Stock · 27,563 shares Expires 2030-12-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,563 shares of the Issuer's common stock, one quarter of which will vest on December 22, 2021, with the remaining three quarters vesting in equal monthly installments through December 22, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.